This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azoulay-Dupuis, E. Articles by Vallee, E. Search for Related Content PubMed PubMed Citation Articles by Azoulay-Dupuis, E. Articles by Vallee, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Apr 1996, 941-946, Vol 40, No. 4
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains

E Azoulay-Dupuis, P Moine, JP Bedos, V Rieux and E Vallee
Institut National de la Sante et de la Recherche Medicale U13, Groupe Hospitalier Bichat-Claude Bernard, Paris, France.

We used a mouse model of pneumococcal pneumonia to assess the bactericidal effect of increasing doses of amoxicillin (AMX) against clinical strains with various susceptibilities to penicillin. Twelve strains that exhibited similar virulence in mice were selected. Three were penicillin susceptible (PS) (penicillin and AMX MICs = 0.01 to 0.03 microgram/ml), three were intermediately resistant (PIR) (penicillin and AMX MICs = 0.5 to 1 microgram/ml), and six were penicillin resistant (PR) (penicillin and AMX MICs = 1 to 8 micrograms/ml). Leukopenic Swiss mice were infected intratracheally with 10(7) CFU of each strain. Treatment was initiated 3 h after infection and consisted of a single subcutaneous injection of AMX at doses ranging from 2.5 to 10 mg/kg (PS strains), 5 to 100 (PIR strains), and 25 to 3,000 (PR strains). Bacterial killing kinetics were recorded in the lungs over 9 h. The maximal log CFU reduction (Emax) was observed 3 h postinjection. The relation between Emax and log10(dose/MIC) showed two populations. With seven strains (the three PS, the three PIR, and one of the six PR [MICs, penicillin/AMX = 4/1]) a good correlation was observed between Emax and log10(dose/MIC) (r = 0.772; P < 0.02). A bactericidal effect equal to 3.5 log10 CFU was observed at a log10(dose/MIC) = 2. At this ratio, with the five other PR strains, Emax varied from 0.4 to 1.6 log10 CFU. In brain heart infusion medium containing AMX at 50 times the relevant MIC, these five PR strains were tolerant in vitro. Treatment failure with AMX was found in vivo, with tolerant, highly resistant strains.

This article has been cited by other articles:

• Abgueguen, P., Azoulay-Dupuis, E., Noel, V., Moine, P., Rieux, V., Fantin, B., Bedos, J.-P. (2007). Amoxicillin Is Effective against Penicillin-Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model Simulating Human Pharmacokinetics. Antimicrob. Agents Chemother. 51: 208-214 [Abstract] [Full Text]  
• Sun, H. K., Lee, S. Y., Banevicius, M. A., Du, X., Maglio, D., Nicolau, D. P. (2005). Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model. J Antimicrob Chemother 56: 559-565 [Abstract] [Full Text]  
• Gracia, M., Martinez-Marin, C., Huelves, L., Gimenez, M. J., Aguilar, L., Carcas, A., Ponte, C., Soriano, F. (2005). Pulmonary Damage and Bacterial Load in Assessment of the Efficacy of Simulated Human Treatment-Like Amoxicillin (2,000 Milligrams) Therapy of Experimental Pneumococcal Pneumonia Caused by Strains for Which Amoxicillin MICs Differ. Antimicrob. Agents Chemother. 49: 996-1001 [Abstract] [Full Text]  
• Sevillano, D., Calvo, A., Gimenez, M.-J., Alou, L., Aguilar, L., Valero, E., Carcas, A., Prieto, J. (2004). Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. J Antimicrob Chemother 54: 1148-1151 [Abstract] [Full Text]  
• Azoulay-Dupuis, E., Mohler, J., Bedos, J. P. (2004). Efficacy of BB-83698, a Novel Peptide Deformylase Inhibitor, in a Mouse Model of Pneumococcal Pneumonia. Antimicrob. Agents Chemother. 48: 80-85 [Abstract] [Full Text]  
• Gustafsson, I., Lowdin, E., Odenholt, I., Cars, O. (2001). Pharmacokinetic and Pharmacodynamic Parameters for Antimicrobial Effects of Cefotaxime and Amoxicillin in an In Vitro Kinetic Model. Antimicrob. Agents Chemother. 45: 2436-2440 [Abstract] [Full Text]  
• Erlendsdottir, H., Knudsen, J. D., Odenholt, I., Cars, O., Espersen, F., Frimodt-Møller, N., Fuursted, K., Kristinsson, K. G., Gudmundsson, S. (2001). Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models. Antimicrob. Agents Chemother. 45: 1078-1085 [Abstract] [Full Text]  
• Azoulay-Dupuis, E., Rieux, V., Muffat-Joly, M., Bédos, J. P., Vallée, E., Rivier, C., Isturiz, R., Carbon, C., Moine, P. (2000). Relationship between Capsular Type, Penicillin Susceptibility, and Virulence of Human Streptococcus pneumoniae Isolates in Mice. Antimicrob. Agents Chemother. 44: 1575-1577 [Abstract] [Full Text]  
• Piroth, L., Martin, L., Coulon, A., Lequeu, C., Duong, M., Buisson, M., Portier, H., Chavanet, P. (1999). Development of a New Experimental Model of Penicillin-Resistant Streptococcus pneumoniae Pneumonia and Amoxicillin Treatment by Reproducing Human Pharmacokinetics. Antimicrob. Agents Chemother. 43: 2484-2492 [Abstract] [Full Text]  
• Bédos, J.-P., Rieux, V., Bauchet, J., Muffat-Joly, M., Carbon, C., Azoulay-Dupuis, E. (1998). Efficacy of Trovafloxacin against Penicillin-Susceptible and Multiresistant Strains of Streptococcus pneumoniae in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 42: 862-867 [Abstract] [Full Text]